Reports 16 May 2023
Outsourcing in life science R&D today
Learn how online platforms facilitate outsourcing in life science R&D.
- Latest Posts
News and Trends 16 May 2023
LabGenius looks to create molecules with huge increase in tumor killing ability
LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […]
News and Trends 16 May 2023
Molsid developing rapid AMR test
Start-up biomed Molsid is developing the first rapid test to detect the potential presence of antimicrobial resistance (AMR) directly in primary clinical samples. ORSET Group and PULSALYS, the SATT in Lyon, extended financing to the company in March 2023. This was followed by the signing of an i-DEMO contract with the French investment bank bpiFrance. […]
News and Trends 16 May 2023
SiSaf siRNA therapy gets FDA designations to treat autosomal dominant osteopetrosis
SiSaf Ltd, an RNA delivery and therapeutics company, has announced that SIS-101-ADO, its siRNA therapeutic for patients with autosomal dominant osteopetrosis Type 2 (ADO2), has been granted orphan drug designation by the U.S. FDA. Also, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted rare pediatric disease designation […]
News and Trends 16 May 2023
Researchers’ mutation discovery offers new Alzheimer’s hope
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated with mutations in the genes APP, PSEN1, and PSEN2, leading to a more aggressive form of the disease with atypical symptoms. In contrast, the newly discovered […]
News and Trends 15 May 2023
New menopause drug gets FDA approval
The U.S. Food and Drug Administration has approved Astellas Pharma’s Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Astellas Pharma US, Inc.’s Veozah is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat moderate to severe hot flashes from […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 15 May 2023
Alzheimer’s drugs could result from immune brain cell discovery
A recent study published in Nature Neuroscience indicates that, contrary to common belief, the immune cells of the brain, known as microglia, are not all the same. Researchers found that a unique microglial subset with unique features and function is important for establishing proper cognitive functions in mice. Evidence for such microglial subsets exists also […]
Best in Biotech 15 May 2023
The six most advanced microbiome players aiming for the gut
After decades of research, gut microbiome therapies are beginning to reach the market. Here are six of the companies harnessing the power of the microbiome to develop treatments derived from the gut. Over the years, gastrointestinal research has increasingly focused on the role of the microbe communities residing in our gut, known collectively as the […]
Best in Biotech 12 May 2023
Five latest advancements in Tourette’s syndrome research
Named after French neurologist Georges Gilles de la Tourette, who first described the disorder in 1885, Tourette’s syndrome is estimated to affect one in 10 to 1000 people worldwide. A neurological condition, the disorder causes involuntary movements and sounds, commonly known as tics. Although its exact cause isn’t known, research points to a link between […]
News and Trends 12 May 2023
DiogenX raises €27.5M for “breakthrough” diabetes treatment
DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, has announced the successful completion of a €27.5 million ($30 million) Series A financing round. New investors Roche Venture Fund, Eli Lilly and Company and Omnes joined this round alongside existing investors Boehringer Ingelheim Venture Fund (BIVF), JDRF T1D Fund, […]
News and Trends 12 May 2023
Achilles Therapeutics’ new platform identifies most potent T-cell antigens
Achilles Therapeutics plc says its newly-developed AI application, trained with proprietary real-world data, outperformed current AI and non-AI methods for neoantigen immunogenicity prediction in a recent analysis, enabling the identification of the most potent clonal neoantigens for personalized cancer therapies. Further details of the company’s AI-powered PELEUS bioinformatics platform are expected to be presented at […]
News and Trends 12 May 2023
Cell and gene therapy company NewBiologix exits stealth with $50M
NewBiologix SA has emerged from stealth as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address key manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to […]
ADVERTISEMENT
